加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01167 加科思-B

未开盘 07-27 16:08:04

5.020

-0.010

-0.20%

最高5.150	最低4.850	成交量115.57万
今开4.990	昨收5.030	日振幅5.96%
总市值39.26亿	流通市值39.26亿	总股本7.82亿
成交额574.80万	换手率0.15%	流通股本7.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01167","market":"HK","secType":"STK","nameCN":"加科思-B","latestPrice":5.02,"timestamp":1785139684002,"preClose":5.03,"halted":0,"volume":1155732,"delay":0,"changeRate":-0.001988071570576675,"floatShares":782000000,"shares":782000000,"eps":-0.2184859620542016,"marketStatus":"未开盘","change":-0.01,"latestTime":"07-27 16:08:04","open":4.99,"high":5.15,"low":4.85,"amount":5747985,"amplitude":0.059642,"askPrice":5.02,"askSize":900,"bidPrice":5,"bidSize":5700,"shortable":3,"etf":0,"ttmEps":-0.2184859620542016,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785202200000},"marketStatusCode":0,"adr":0,"listingDate":1608480000000,"exchange":"SEHK","adjPreClose":5.03,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":0.38977153417271154,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01167","defaultTab":"news","newsList":[{"id":"2654606740","title":"加科思-B(01167.HK)：完成BET抑制剂JAB-8263用于类风湿关节炎的IIa期临床试验在中国的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2654606740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654606740?lang=zh_cn&edition=full","pubTime":"2026-07-27 06:53","pubTimestamp":1785106397,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132175725","title":"加科思-B（01167）BET抑制剂JAB-8263在华完成类风湿关节炎IIa期首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1132175725","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132175725?lang=zh_cn&edition=full","pubTime":"2026-07-27 06:46","pubTimestamp":1785105968,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司7月27日自愿公告，其自主研发的高活性BET抑制剂JAB-8263用于类风湿关节炎的IIa期临床试验已在中国完成首例患者给药。这是全球首个在RA领域开展临床试验的BET抑制剂项目，标志着该产品管线由肿瘤拓展至自身免疫疾病领域。加科思强调，JAB-8263拥有全球知识产权，作为口服小分子药物，预计可通过调节表观遗传状态改善患者长期治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164427729","title":"加科思-B：7月24日回购9.90万股，耗资约49.70万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164427729","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164427729?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:42","pubTimestamp":1784889734,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司(01167)于2026年7月24日公布翌日披露报表，显示公司当日通过香港联交所场内回购股份9.90万股，占彼时公司已发行股本约0.01266%。每股回购价介乎每股5.01港元至5.03港元，合计耗资约49.70万港元。\n回购完成后，公司已发行股本总数保持791,755,080股，其中包括流通股782,178,180股及库存股9,576,900股。根据2026年6月5日通过的回购授权，公司可回购股份上限为78,372,528股，其中已回购1,547,100股。\n公司在公告中确认已遵守相关上市规则和适用法律法规。公告由董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B：7月24日回购9.90万股，耗资约49.70万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121939586","title":"加科思-B7月23日回购9.78万股，耗资约49.73万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121939586","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121939586?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:46","pubTimestamp":1784807216,"startTime":"0","endTime":"0","summary":"2026年7月23日，加科思药业集团有限公司发布翌日披露报表，公告当日在香港联交所场内进行股份回购。公告显示，公司于7月23日回购普通股9.78万股，约占本次回购前已发行股本的0.0125%，每股回购价介乎5.03港元至5.12港元，总耗资497,268港元。公司于2026年6月5日获得购回授权，授权可回购股份总数为78,372,528股。截至目前，基于该授权已回购1,448,100股，剩余可回购股份额度为76,924,428股。公告由董事王晓洁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B7月23日回购9.78万股，耗资约49.73万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653429207","title":"加科思-B(01167)7月23日斥资49.7万港元回购9.78万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653429207","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653429207?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:37","pubTimestamp":1784806657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年7月23日斥资49.7万港元回购9.78万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135489982","title":"加科思-B7月21日回购9.84万股，涉资约49.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135489982","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135489982?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:02","pubTimestamp":1784635348,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月21日发布公告，披露当日进行了股份购回。公告显示，公司当日回购98,400股普通股，占回购前已发行股本约0.01258%。每股购回价格介乎港币5.06元至5.08元，合计涉资港币49.86万元。回购完成后，公司已发行股份数目为782,374,980股，库藏股数目为9,380,100股。购回授权于2026年6月5日获通过，公司可根据该授权购回股份总数为78,372,528股，已累计购回1,350,300股。本次公告由董事王晓洁签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B7月21日回购9.84万股，涉资约49.86万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272527","title":"加科思-B(01167)7月21日斥资49.86万港元回购9.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272527","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653272527?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:52","pubTimestamp":1784634762,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年7月21日斥资49.86万港元回购9.84万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652267235","title":"港股异动 | 加科思-B(01167.HK)午后涨超8% JAB-23E73联合化疗试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652267235","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652267235?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:12","pubTimestamp":1784527961,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652688822","title":"加科思-B(01167)：完成泛KRAS抑制剂JAB-23E73联合化疗用于KRAS突变胰腺癌一线 治疗之Ib/III期临床试验在中国的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652688822","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652688822?lang=zh_cn&edition=full","pubTime":"2026-07-20 06:42","pubTimestamp":1784500970,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B 发布公告，本公司的泛KRAS抑制剂JAB-23E73联合白蛋白结合型紫杉醇及吉西他滨用于KRAS突变胰腺癌一线治疗之Ib/III期临床试验在中国完成首例患者给药。本项研究的启动依托此前公布在本公司2025年度年度报告中并仍在推进的I期临床试验所取得的喜人初步临床数据。KRAS突变在胰腺癌中发生率极高。本项研究正式启动，是JAB-23E73研发进程中的重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4134","BK1574","IBBQ","01167","BMED","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128857756","title":"加科思-B（01167）宣布JAB-23E73联合方案在华Ib/III期试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1128857756","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128857756?lang=zh_cn&edition=full","pubTime":"2026-07-20 06:41","pubTimestamp":1784500891,"startTime":"0","endTime":"0","summary":"2026年7月20日，加科思-B发布自愿公告称，其自主研发的口服泛KRAS抑制剂JAB-23E73联合白蛋白结合型紫杉醇及吉西他滨，用于KRAS突变胰腺癌一线治疗的Ib/III期临床试验已在中国完成首例患者给药。该研究基于加科思在2025年年度报告中披露并仍在推进的I期临床试验数据。加科思表示，KRAS突变在胰腺癌中发病率较高，此次研究正式启动是JAB-23E73研发进程的重要里程碑。公司提醒投资者，根据香港联交所证券上市规则第18A.05条，无法保证JAB-23E73最终能够成功开发及商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128799017","title":"加科思-B回购10.5万股股份，总额约48.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128799017","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128799017?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:21","pubTimestamp":1784290917,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月17日发布公告，披露公司于香港联交所场内回购了105,000股，占回购前公司已发行股本的约0.01342%。据公告显示，本次回购价格区间介于每股港币4.64元至4.66元，合计耗资约48.78万港元。回购完成后，公司于2026年7月17日的已发行股份数变更为782,473,380股，库藏股则增加至9,281,700股，合并后公司股本总数仍为791,755,080股。公告称，上述回购基于2026年6月5日通过的股份回购授权进行，授权回购股份总数为78,372,528股，迄今已回购的股份累计1,251,900股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B回购10.5万股股份，总额约48.78万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652288708","title":"加科思-B(01167)7月17日斥资48.8万港元回购10.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652288708","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652288708?lang=zh_cn&edition=full","pubTime":"2026-07-17 20:19","pubTimestamp":1784290769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年7月17日斥资48.8万港元回购10.5万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182406145","title":"加科思-B回购约10.17万股股份，总额约49.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182406145","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182406145?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:50","pubTimestamp":1783950650,"startTime":"0","endTime":"0","summary":"加科思-B于2026年7月13日公布翌日披露报表，公司在香港联交所场内回购股份，涉及约101,700股普通股，约占当日公司现有已发行股份的0.01299%。最高回购价为每股4.92港元，最低回购价为每股4.90港元，合计支付约49.87万港元。回购完成后，公司已发行股份数量变更为约782,680,380股，库藏股增至约9,074,700股，合计已发行股本为约791,755,080股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B回购约10.17万股股份，总额约49.87万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651432112","title":"加科思-B(01167)7月13日耗资约49.87万港元回购10.17万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651432112","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651432112?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:47","pubTimestamp":1783950440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)公布，2026年7月13日耗资约49.87万港元回购10.17万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01167","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134289117","title":"加科思-B回购10.11万股，耗资约49.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134289117","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134289117?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:50","pubTimestamp":1783601450,"startTime":"0","endTime":"0","summary":"加科思-B于2026年7月9日发布翌日披露报表，公布当日于香港联交所回购101,100股普通股，回购股份占回购前公司已发行股本约0.01291%。此次回购价格区间为每股港币4.93元至4.95元，合计支付约49.94万港元。公司表示，其回购授权于2026年6月5日获股东大会通过，授权回购股份总数为78,372,528股，截至目前已根据授权在香港联交所购回股份943,200股，约占当日获授权时已发行股本的0.12035%。公司确认已遵守香港联交所证券上市规则及相关法例的规定。本次公告由董事王晓洁签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B回购10.11万股，耗资约49.94万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156860148","title":"加科思-B：7月8日回购101,700股，耗资约49.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156860148","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156860148?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:42","pubTimestamp":1783518136,"startTime":"0","endTime":"0","summary":"加科思-B于2026年7月8日发布翌日披露报表，宣布于当天在香港联交所场内回购101,700股普通股，占公司截至该次回购前已发行股本的约0.01299%。根据公告，公司本次回购依据于2026年6月5日通过的购回授权进行，授权范围内可再购回78,372,528股，截至目前，累计在香港联交所及其他证券交易所已购回合共842,100股，占授权通过当日已发行股份约0.10745%。公司确认本次回购已遵守香港联交所相关上市规则及适用法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"加科思-B：7月8日回购101,700股，耗资约49.88万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649776999","title":"加科思-B(01167.HK)7月8日斥资49.9万港元回购10.17万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649776999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649776999?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:41","pubTimestamp":1783518082,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103038233","title":"加科思-B回购101,100股股份，合计耗资约49.92万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103038233","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103038233?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:28","pubTimestamp":1783420093,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月7日发布公告称，公司于当日在香港联合交易所回购101,100股股份，占回购前现有已发行股本的0.01291%。此次回购每股价格介乎港币4.92元至4.95元，总计支付对价约499,185港元。本次回购股份将被列作库存股份。本次回购完成后，公司已发行股份总数保持在791,755,080股，其中流通股份数为782,984,880股，库存股份数为8,770,200股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加科思-B回购101,100股股份，合计耗资约49.92万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649894529","title":"加科思-B(01167)7月7日斥资49.92万港元回购10.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649894529","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649894529?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:21","pubTimestamp":1783419660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年7月7日，该公司斥资49.92万港元回购10.11万股股份，每股回购价4.92-4.95港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166069602","title":"加科思-B更新6月股份变动月报表，当月回购976,500股","url":"https://stock-news.laohu8.com/highlight/detail?id=1166069602","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166069602?lang=zh_cn&edition=full","pubTime":"2026-07-07 10:37","pubTimestamp":1783391830,"startTime":"0","endTime":"0","summary":"加科思药业集团有限公司于2026年7月7日发布截至2026年6月30日止的股份变动月报表，披露了公司注册股本及股份变动等情况。期末已发行股份总数为791,755,080股，其中，流通股份783,085,980股，库存股份8,669,100股。报告期内，公司无新增发行或注销股份，发生了累计976,500股的股份回购活动，并将所回购股份列作库存股份。截至本月底，公司确认已符合香港联合交易所有限公司相关公众持股量要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jacobiopharma.com","stockEarnings":[{"period":"1week","weight":-0.029},{"period":"1month","weight":0.1756},{"period":"3month","weight":-0.2969},{"period":"6month","weight":-0.1968},{"period":"1year","weight":-0.3289},{"period":"ytd","weight":-0.2119}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.1118},{"period":"3month","weight":-0.0184},{"period":"6month","weight":-0.0941},{"period":"1year","weight":-0.0071},{"period":"ytd","weight":-0.0165}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"加科思药业集团有限公司是一家主要从事临床阶段新药研发的投资控股公司。该公司主要负责创新肿瘤疗法的自主发现和开发。该公司主要药物开发项目包括JAB-21822及JAB-3312临床阶段的变构SHP2抑制剂。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.0037},{"month":2,"riseRate":0.5,"avgChangeRate":0.158834},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.004688},{"month":4,"riseRate":0.666667,"avgChangeRate":0.034456},{"month":5,"riseRate":0.333333,"avgChangeRate":0.005017},{"month":6,"riseRate":0,"avgChangeRate":-0.071939},{"month":7,"riseRate":0.5,"avgChangeRate":0.069916},{"month":8,"riseRate":0.2,"avgChangeRate":0.005746},{"month":9,"riseRate":0.6,"avgChangeRate":-0.002238},{"month":10,"riseRate":0.2,"avgChangeRate":-0.065405},{"month":11,"riseRate":0.4,"avgChangeRate":0.020921},{"month":12,"riseRate":0.2,"avgChangeRate":-0.06824}],"exchange":"SEHK","name":"加科思-B","nameEN":"JACOBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"加科思-B,01167,加科思-B股票,加科思-B股票老虎,加科思-B股票老虎国际,加科思-B行情,加科思-B股票行情,加科思-B股价,加科思-B股市,加科思-B股票价格,加科思-B股票交易,加科思-B股票购买,加科思-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"加科思-B(01167)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供加科思-B(01167)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}